Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Cash & Equivalents (2016 - 2025)

INVO Fertility (IVF) has disclosed Cash & Equivalents for 15 consecutive years, with $400000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 20.0% to $400000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $400000.0, a 20.0% decrease, with the full-year FY2024 number at $619520.0, up 166.55% from a year prior.
  • Cash & Equivalents was $400000.0 for Q3 2025 at INVO Fertility, down from $549181.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $8.4 million in Q1 2021 to a low of $90135.0 in Q4 2022.
  • A 5-year average of $2.1 million and a median of $840407.0 in 2025 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 2306.64% in 2021, then plummeted 98.41% in 2022.
  • INVO Fertility's Cash & Equivalents stood at $5.7 million in 2021, then tumbled by 98.41% to $90135.0 in 2022, then skyrocketed by 157.86% to $232424.0 in 2023, then surged by 166.55% to $619520.0 in 2024, then tumbled by 35.43% to $400000.0 in 2025.
  • Per Business Quant, the three most recent readings for IVF's Cash & Equivalents are $400000.0 (Q3 2025), $549181.0 (Q2 2025), and $840407.0 (Q1 2025).